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People who inject drugs
PWID
Sero- and behavioural survey
A B S T R A C T
Background: People who inject drugs (PWID) are at high risk of hepatitis B virus (HBV) infection by
sharing needles and drug use paraphernalia. In Germany, no routine surveillance of HBV prevalence and
vaccination coverage among PWID exists.
Methods: Socio-demographic and behavioural data were collected between 2011 and 2014 through face-
to-face interviews, during a bio-behavioural survey of PWID recruited in eight German cities. Dried blood
spots (DBS) prepared with capillary blood were tested for HBV markers. Factors associated with past/
current HBV infection and vaccination status were analysed by univariable and multivariable analysis
using logistic regression. The validity of self-reported HBV infection and vaccination status was analysed
by comparison to the laboratory results.
Results: Among 2077 participants, the prevalence of current HBV infection was 1.1%, of past HBV infection
was 24%, and of vaccine-induced HBV antibodies was 32%. No detectable HBV antibodies were found in
43%. HBV infection status was significantly associated with study city, age, years of injecting, use of
stimulants, migration status, and homelessness; HBV vaccination status was significantly associated with
study city, age, and level of education. Correct infection status was reported by 71% and correct
vaccination status by 45%.
Conclusions: HBV seroprevalence among PWID was about five times higher than in the general population
in Germany, confirming PWID as an important risk group. Targeted information campaigns on HBV and
HBV prevention for PWID and professionals in contact with PWID need to be intensified. Routinely
offered HBV vaccination during imprisonment and opioid substitution therapy would likely improve
vaccination rates among PWID.
© 2017 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Evidence before the study
People who inject drugs (PWID) are at risk of blood-borne and
sexually transmitted infections, such as hepatitis B virus (HBV)
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).information on HBV among PWID in Germany, and routine
monitoring of infections or risk behaviours among PWID has not
yet been established. Knowledge on HBV prevalence and vaccina-
tion coverage in this population in Germany is based on outdated
regional studies, which found markers of former HBV infection in
35–62% of study participants and low vaccination coverage. HBV
vaccination has been recommended and implemented in Germany
for PWID since 1982, and for all children since 1995, but the
coverage among PWID is largely unknown. Several studies from
other countries that have included smaller numbers of participants
have suggested limited validity of self-reported HBV infection and
vaccination status for PWID.ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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The seroprevalence of current HBV infection among 2077 PWID
in this study was found to be about five times higher than that in
the general population in Germany, indicating that PWID are an
important group at risk of HBV infection. Despite a clear national
vaccination recommendation, a large proportion of PWID remains
at risk of infection, as suggested by the absence of infection- or
vaccine-induced antibodies. Settings in which PWID could easily
be reached for vaccination (opioid substitution treatment (OST) or
prisons) were found not to be associated with higher proportions
of vaccinated PWIDs, hinting at missed opportunities for vaccina-
tion. The in-depth analysis of key factors associated with HBV
infection and vaccination among this key risk group makes this
study highly relevant for public health practitioners and policy-
makers working on improving the health of PWID. Furthermore,
the limited validity of self-reported HBV infection and vaccination
status among PWID argues for pre-emptive vaccination of PWID if
no vaccination record is available.
Implications of all the available evidence
This study shows the need for targeted information campaigns
for PWID and professionals in contact with PWID on HBV and HBV
prevention, despite national vaccination recommendations in-
cluding both the recommendation of universal infant and child
vaccination (since 1995) and risk group vaccination (starting in
1982) in Germany. The authors recommend intensifying efforts to
ensure that HBV vaccination is routinely offered during OST and
imprisonment in order to improve HBV vaccination coverage
among PWID. The strong association of the study city particularly
with HBV vaccination status, and less so with infection status,
indicates an effect of the local setting. Further studies to evaluate
local differences, e.g., in practices and efforts of medical doctors
offering OST and local HBV vaccination and on information
campaigns/programs and their impact, might identify additional
effective measures and good practices to improve vaccination
coverage.
Introduction
People who inject drugs (PWID) are at high risk of hepatitis B
virus (HBV) infection through blood-borne transmission by sharing
needles and drug use paraphernalia, as well as through unsafe sex.
Worldwide, an estimated 12.7 million people inject drugs (United
Nations Office on Drugs and Crime, 2014), and 6.4 million PWID are
hepatitis B core antigen antibody (anti-HBc)-positive and 1.2
million are hepatitis B surface antigen (HBsAg) positive (Nelson
et al., 2011). National estimates of HBsAg prevalence among PWID
from seven European countries range from 0.5% to 6.3% (European
Centre for Disease Prevention and Control, 2016). In Germany, data
from routine reporting suggest that PWID constitute one of the
main groups affected by HBV, in addition to migrants and men who
have sex with men (Robert Koch-Institut (RKI), 2016). HBV
outbreaks among PWID have been repeatedly reported in Europe
over the past years (Andersson et al., 2012; Christensen et al.,
2001). Studies have identified several risk factors associated with
HBV infections among PWID, including age >25 years, sharing
needles/syringes, history of needle/syringe sharing in prison, long
duration of injecting drug use, homelessness, and unemployment
(Andersson et al., 2012; Removille et al., 2011; Stark et al., 1997;
Brack, 2002).
International recommendations of the European Centre for
Disease Prevention and Control (ECDC), the European Monitoring
Centre for Drugs and Drug Addiction (EMCDDA), and the World
Health Organization (WHO) on the prevention of HBV amongPWID emphasize the importance of vaccination (World Health
Organization, 2012; European Centre for Disease Prevention and
Control and European Monitoring Centre for Drugs and Drug
Addiction, 2011). An effective, affordable, and safe subunit vaccine
against HBV has been available since 1982. The WHO recommends
vaccinating all infants after birth with the first of three to four
vaccination doses (World Health Organisation (WHO), 2009). Since
1995, the German Standing Committee on Vaccination (STIKO) has
recommended vaccinating all infants. Data collected between
2008 and 2011 indicated that 23% of adults in Germany had been
vaccinated against HBV, with an increasing proportion in the
younger age groups (57% among the 20–29-year-olds) (Poethko-
Muller et al., 2013). Since 1982 (West Germany) and 1984 (East
Germany), HBV vaccination of groups at increased risk, such as
PWID and prisoners, has been recommended. Worldwide, several
studies have found low HBV vaccine coverage among PWID
(Quaglio et al., 2006).
There have been no recent studies providing up-to-date
information on HBV among PWID in Germany, and routine
monitoring of infections or risk behaviours among PWID has not
yet been established. Knowledge on HBV prevalence and vaccina-
tion coverage among PWID in Germany is based on outdated
regional studies, which found markers of former HBV infection in
35–62% of the study participants and low vaccination coverage
(Stark et al., 1997; Brack, 2002; Ridder et al., 2004).
This analysis is based on data from a bio-behavioural survey of
PWID recruited in eight large German cities, performed between
2011 and 2014. The objective of this analysis was to describe the
HBV infection status and vaccination status of PWID and to identify
factors associated with current or past HBV infection, as well as for
not being vaccinated against HBV. Whether self-reported HBV
infection status and HBV vaccination status were supported by
serological test results was also investigated. This was done in
order to develop recommendations for improved HBV vaccination
coverage and HBV prevention among PWID.
Methods
Sampling and recruitment
Biological and behavioural data were collected from 2077 PWID
in eight large German cities between 2011 and 2014 (Zimmermann
et al., 2014). Study participants were recruited through respon-
dent-driven sampling (RDS) in up to four local low-threshold drug
services in each of the eight study cities (Berlin, Essen, Leipzig,
Cologne, Munich, Frankfurt am Main, Hanover, and Hamburg).
Inclusion criteria were age 16 years, having injected drugs in the
given study city in the last 12 months, and providing informed
consent for study participation. The study was piloted in Berlin and
Essen. All participants attended a questionnaire-assisted interview
and provided a capillary blood sample. Detailed information on the
study design and recruitment process has been published
previously (Zimmermann et al., 2014; Wenz et al., 2016).
Socio-demographic and behavioural data
Face-to-face-interviews included questions on socio-demo-
graphic factors, substances consumed, risk and preventive
behaviours, and HBV infection and vaccination. Minor modifica-
tions to the questionnaire were made throughout the survey.
Therefore, certain variables are not available for all cities. In the
first three cities (Berlin, Essen, and Leipzig), participants were not
asked whether they had ever been offered HBV vaccination. The
setting of the last vaccination was not queried in Berlin and Essen.
Migration status was defined by country of birth: first-
generation migrants were not born in Germany and second-
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parents were not born in Germany. The level of education was
categorized following the International Standard Classification of
Education (ISCED). This was determined by querying the highest
school education and highest professional formation. If the highest
level of professional formation was missing, the highest school
education was used as the highest education level. The use of
stimulant drugs was defined as the consumption of amphetamine,
methamphetamine, cocaine, crack, or 3,4-methylenedioxyme-
thamphetamine (MDMA) during the last 30 days, regardless of
the mode of consumption. Unsafe use was defined as using shared
needles/syringes or spoons/filters, or sharing water for intravenous
drug consumption in the past 30 days. Condom use during the last
vaginal or anal intercourse was queried among participants who
reported sex in the past 12 months.
Defining correct knowledge of own HBV infection and vaccination
status
The self-reported HBV infection status was determined by
asking whether the participant had ever been tested for HBV and if
yes, what the result of the latest test was. Based on the answers,
participants were categorized as HBV-negative, HBV-positive, or
‘don’t know’. The self-reported HBV vaccination status was
determined by asking if the participant had ever been vaccinated
against HBV. Participants with laboratory-confirmed current or
past HBV infection were excluded from this analysis. The validity of
the self-reported HBV infection and vaccination status was
determined by comparing self-reported and laboratory tested
status.
Biological data collection and laboratory analysis
Capillary blood samples were collected from each participant
by finger prick and spotted on filter cards to prepare dried blood
spots (DBS). DBS testing for this study was validated during the
pilot (Ross et al., 2013). DBS were tested for HBsAg (only during the
pilot study in Berlin and Essen), HBV-DNA, hepatitis B surface
antigen antibodies (anti-HBs), and hepatitis B core antigen
antibodies (anti-HBc) (all study cities); genotypes were deter-
mined as described previously (Zimmermann et al., 2014; Al
Baqlani et al., 2014).
The interpretation of HBV laboratory results was performed
according to German clinical guidelines (Cornberg et al., 2011)
(Table 1). Samples with exclusive detection of anti-HBs antibodies
with a detection limit of 10 IE/l were interpreted as HBV
vaccinated. HBV seroprevalence was defined as current or past
HBV infection. Samples negative for all tested HBV markers were
interpreted as unexposed to HBV.Table 1
Classification of serological and molecular markers for HBV diagnostics.a
HBV status HBV marker
anti-HBs anti-HBc HBV-DNA/HBsAg
Unexposed   
HBV vaccinated +  
Current HBV infection (+) (+) +
Past HBV infection (+) + 
HBV, hepatitis B virus; anti-HBs, hepatitis B surface antibody; anti-HBc, hepatitis B
core antibody; HBsAg, hepatitis B surface antigen.
a ‘+’ indicates detection of HBV marker; ‘(+)’ indicates detection of HBV marker
irrelevant for classification of HBV infection status; ‘’ indicates no detection of HBV
marker.Statistical analysis
Results are shown as the range of proportions (minimum and
maximum values (%)) in the study cities. Univariable and
multivariable analysis (UVA and MVA) were performed using
logistic regression. To analyse the effect of the study city, a city with
a medium prevalence was chosen as reference. For the MVA,
models were built using stepwise forward selection by adding
factors with a p-value lower than 0.2 in the UVA. Multivariable
models were adjusted for sex and were retained only if the p-value
was <0.05 in the likelihood ratio test. For the analysis of factors
influencing HBV infection, HBV vaccinated participants were
excluded. For the analysis of factors influencing HBV vaccination,
participants with current/past HBV infection were excluded. All
data analyses were performed using Stata version 14.0.
Ethics approval and data protection
Ethical approval was received from the Ethics Committee at
Charité University Medicine, Berlin, Germany, in 2011 (Number
EA4/036/11) and in 2012 (amendment; Number EA4/036/11). The
Federal Commissioner for Data Protection and Freedom of
Information approved the study protocol in 2012 (III-401/
008#0035). All participants provided informed consent allowing
their anonymized data to be used for publication. Participants were
also allowed to give oral informed consent, which was then
certified by the study manager’s signature on the informed consent
form. Informed consent forms and questionnaires were sent to the
Robert Koch Institute where data entry and analysis were
performed. Informed consent forms were stored separately from
questionnaires, with restricted access only to study personnel.
Participants were offered the option to receive their test results by
consenting on a personal code word. In such cases, post-test
counselling was provided. In each of the study cities, referral
structures were organized so that persons who voluntarily
received their test result could be referred to medical care for
further diagnostics and treatment, if necessary.
Results
Among the 2077 participants, the proportion of women among
the study cities ranged from 19% to 35%; the median age of
participants was 29–41 years and median duration of injecting
drugs was 10–18 years. Between 76% and 88% of participants
reported injecting in the last 30 days, and 57–85% reported heroin
consumption in this period. Other characteristics and drug
consumption practices of the study population have been
published elsewhere (Wenz et al., 2016).
HBV seroprevalence and prevalence of vaccine-induced HBV
antibodies
The prevalence of current HBV infection was 1.1% (n = 22) (city
range 0.3–2.5%) and the prevalence of cleared HBV infection was
24% (n = 494) (city range 2.3–31%). HBV seroprevalence among all
study participants was 25% (n = 516) (city range 4.3–32%). Similar
to HBV seroprevalence, prevalence of HBV vaccination-induced
HBV antibodies varied between study cities (city range 15–52%),
with an average of 32% among all study participants. Across all
study cities, 43% of study participants (city range 16–69%) had no
antibodies against HBV through vaccination or natural immunity
after HBV infection (Figure 1, Table 2).
HBV seroprevalence increased with age and was 3%, 17%, and
37% in the age groups <25 years, 25–39 years, and 40 years,
respectively. Current HBV infections were detected in 0.7% within
the age group of 25–39 years and in 1.6% of those 40 years old. No
Figure 1. Serological and molecular findings for HBV status by study city.
Table 2
HBV status (according to laboratory findings) by age group, sex, and HIV and HCV status.
Unexposed Vaccinated Current HBV infection Past HBV infection
Age group <25 years (n = 135) 63 (47%) 68 (50%) 0 (0.0%) 4 (3.0%)
25–39 years (n = 1018) 503 (49%) 341 (34%) 7 (0.7%) 167 (16%)
40 years (n = 922) 323 (35%) 261 (28%) 15 (1.6%) 323 (35%)
Sex Male (n = 1594) 690 (43%) 493 (31%) 17 (1.1%) 394 (25%)
Female (n = 480) 198 (41%) 178 (37%) 4 (0.8%) 100 (21%)
HIV status Negative (n = 1977) 855 (43%) 639 (32%) 19 (1.0%) 464 (23%)
Positive (n = 100) 35 (35%) 32 (32%) 3 (3.0%) 30 (30%)
HCV status Negative (n = 716) 376 (53%) 253 (35%) 2 (0.3%) 85 (12%)
Positive (n = 1361) 514 (38%) 418 (31%) 20 (1.5%) 409 (30%)
Total (n = 2077) 890 (43%) 671 (32%) 22 (1.1%) 494 (24%)
HBV, hepatitis B virus; HIV, human immunodeficiency virus; HCV, hepatitis C virus.
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Among all study participants, the HBV seroprevalence was higher
among men than women (26% vs. 22%) (Table 2).
HBV genotypes
HBV genotyping was performed on 16 samples with active HBV
infection (no genotyping was performed in Berlin or Essen). The
most frequently identified genotype was D (n = 12), followed by A
(n = 3) and G (n = 1). Other HBV genotypes were not detected.
Knowledge of correct HBV infection status
Self-reported and laboratory-tested HBV infection status were
concordant in 71% (n = 1463), indicating correct knowledge of theirTable 3
Self-reported HBV infection status and comparison to laboratory tested HBV infection 
Self-reported HBV infection status
HBV laboratory test result Not infected 
Unexposed 663 (32%)a
Current/past infection 165 (8.0%) 
Vaccinated 498 (24%)a
Total 1326 (65%) 
HBV, hepatitis B virus.
a Concordant results.own HBV infection status. Among study participants, 9.3% (n = 190)
stated that they did not know their HBV infection status. Among
the participants who had a past or current HBV infection, 41%
(n = 209/511) were unaware of their infection. Among all study
participants, 11% (n = 233) thought they had been or were currently
infected with HBV, although their laboratory results indicated
neither previous vaccination nor contact with HBV (Table 3).
Factors associated with HBV infection status
In the UVA, participant age 25 years (reference: <25 years),
injecting drugs for more than 10 years, using stimulant drugs in the
past 30 days, and ever having been incarcerated or in opioid
substitution therapy (OST), were significantly associated with
current/past HBV infection (Table 4). Furthermore, the HBVstatus among patients with a valid answer on infection status (n = 2051).
Infected Don’t know Total
117 (5.7%) 98 (4.8%) 878 (43%)
302 (15%)a 44 (2.2%) 511 (25%)
116 (5.7%) 48 (2.3%) 662 (32%)
535 (26%) 190 (9.3%) 2051 (100%)
Table 4
Univariable and multivariable analysis of factors associated with HBV infection (n = 1406).
Current/past HBV infection Univariable analysis Multivariable analysis
OR 95% CI aOR 95% CI
Study city Frankfurt 38% Ref. Ref.
Leipzig 6.3% 0.1 *** 0.0–0.3 0.2 *** 0.1–0.4
Berlin 19% 0.4 *** 0.3–0.6 0.5 ** 0.3–0.8
Cologne 35% 0.9 0.6–1.3 0.8 0.6–1.3
Hamburg 47% 1.5 1.0–2.2 1.2 0.8–1.8
Essen 43% 1.2 0.8–1.8 1.4 0.9–2.2
Munich 51% 1.7 * 1.1–2.6 1.9 * 1.1–3.1
Hanover 67% 3.2 *** 2.0–5.2 3.2 *** 1.9–5.3
Sex Male 34% Ref. Ref.
Female 37% 0.9 0.7–1.2 1.1 0.8–1.5
Age (years) <25 6.0% Ref. Ref.
25–39 26% 5.4 ** 2.0–15 2.2 0.7–6.4
40 51% 16.5 *** 5.9–46 5.3 * 1.8–16
Duration of IV drug use <10 years 15% Ref. Ref.
>10 years 44% 4.6 *** 3.3–6.4 2.8 *** 1.9–4.0
Use of stimulant drugs (past 30 days) No 31% Ref. Ref.
Yes 40% 1.5 ** 1.2–1.9 1.6 ** 1.2–2.1
Migrant status Non-migrant 38% Ref. Ref.
2nd generation 32% 0.8 0.6–1.1 0.9 0.6–1.2
1st generation 37% 1.0 0.7–1.3 1.5 ** 1.1–2.0
Ever been homeless No 34% Ref. Ref.
Yes 38% 1.2 0.9–1.5 1.4 * 1.1–1.8
Ever incarcerated No 29% Ref.
Yes 38% 1.5 ** 1.1–2.1
Ever in opioid substitution therapy No 24% Ref.
Yes 40% 2.1 *** 1.5–2.8
Unsafe use (past 30 days) No unsafe use 40% Ref.
No IV drug use 30% 0.6 ** 0.5–0.9
Unsafe use 34% 0.8 * 0.6–1.0
Condom use during last vaginal/anal intercourse Yes 36% Ref.
No sex past 12 months 42% 1.3 1.0–1.8
No 35% 0.9 0.7–1.2
HBV, hepatitis B virus; OR, odds ratio; aOR, adjusted odds ratio; CI, confidence interval; IV, intravenous.
* p < 0.05.
** p < 0.01.
*** p < 0.001.
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Participants injecting drugs in Munich and Hanover more often
had a current/past HBV infection compared to participants from
the other cities. Migrant status, ever having been homeless, and
condom use during the last vaginal/anal intercourse were not
associated with HBV infection status in the UVA. Participants who
stated either unsafe use or no intravenous drug use in the past 30
days (reference: no unsafe use) had significantly lower odds of
having a current/past HBV infection.Table 5
Self-reported and laboratory tested HBV vaccination status among patients with a valid
infection (n = 1553).
Self-reported HBV vaccination statu
HBV laboratory test result Not vaccinated 
Unexposed 353 (23%)a
Vaccinated 239 (15%) 
Total 592 (38%) 
HBV, hepatitis B virus.
a Concordant results.In the MVA, study participant age 40 years (reference: <25
years), injecting drugs for more than 10 years, having used
stimulant drugs in the past 30 days, being a first-generation
migrant (reference: non-migrant), and having ever been homeless
was associated with higher odds of having a current/past HBV
infection. As in the UVA, the study city was also significantly
associated with the HBV status.
Incarceration, unsafe use, OST experience, and condom use
during the last vaginal/anal intercourse were not significantly answer on vaccination status and with no laboratory-confirmed current/past HBV
s
Vaccinated Don’t know Total
407 (26%) 125 (8.1%) 885 (57%)
349 (22%)a 80 (5.2%) 668 (43%)
756 (49%) 205 (13%) 1553 (100%)
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(Table 4).
Knowledge of correct HBV vaccination status
Among participants with no laboratory-confirmed current/past
HBV infection, 45% (n = 702) of self-reported and laboratory-tested
HBV vaccination status results were concordant, indicating correct
knowledge of their HBV vaccination status. Among participants,
13% (n = 205) stated that they did not know their HBV vaccination
status. Falsely assuming not being vaccinated against HBV was the
case for 15% (n = 239) of participants. Among participants with
neither vaccine-induced nor infection-induced detectable anti-
bodies against HBV, 26% (n = 407) stated that they had been
vaccinated against HBV (Table 5).
Setting of last HBV vaccination
Among participants who reported having been vaccinated
against HBV (n = 938), 641 answered the question about the setting
or place of their last vaccination. The most frequently reported
settings were medical doctors without addiction therapy, e.g.
general practitioners (34%), OST services (23%), and hospitals (17%)
(Figure 2).
Factors associated with HBV vaccination status
The UVA showed that injecting drugs in Berlin, belonging to age
group 25–39 years, having a high education level, ever having been
incarcerated, and never having been in OST, were significantly
associated with testing negative for vaccine-induced HBV anti-
bodies (Table 6). In the MVA, participants who injected drugs in
Berlin, belonged to the age group 25–39 years (reference: <25
years), and had a high education level (reference: low education
level) were significantly associated with not having vaccine-
induced HBV antibodies. No association was found in the MVA for
incarceration and OST (Table 6).
Discussion
The HBV seroprevalence among PWID in this study was about
five times higher than that in the general population in Germany,Figure 2. Place of last HBV vaccination (n = 641). Question not asked in Berlin, Essen, or 
medical doctors/outpatient clinics with OST or addiction therapy.confirming PWID as an important risk group for HBV (Poethko-
Muller et al., 2013). Furthermore, despite the existing recom-
mendations of STIKO for the vaccination of PWID against HBV,
neither vaccine-induced antibodies nor any natural immunity
from past HBV infection were detected in 43% of participants,
therefore leaving them at risk of infection. This suggests that the
German vaccination recommendation for PWID and other groups
at increased risk of HBV infection has not been reaching this group
sufficiently. It is noteworthy that the study participants often had
several indications for HBV vaccination besides intravenous drug
use, e.g. HIV infection, hepatitis C virus (HCV) infection, or
incarceration experience. However, young study participants (<25
years of age) showed a higher proportion of vaccine-induced
immunity and a lower prevalence of HBV infection than those in
the older age groups, indicating that they had already been covered
by the general vaccination recommendation for infants imple-
mented in 1995. Catch-up campaigns for older children were
conducted to immunize children <19 years of age, but they were
not systematically implemented and conducted on a large scale. In
line with this, a higher proportion of vaccine-induced immunity
among those aged 25–39 years was not observed; this age group
represents a population that might have benefited from the
general vaccination recommendation in childhood.
In this study, age 40 years and duration of intravenous drug
use of more than 10 years was significantly associated with
current/past HBV infections. This finding is biologically plausible,
as it correlates with longer lifetime exposure to HBV and is in good
agreement with several other studies (Removille et al., 2011; Edeh
and Spalding, 2000). Further, first-generation migrants have higher
odds of current/past HBV infection than non-migrants, similar to
the results of the national German children and adolescents survey
(Cai et al., 2011). This could be explained either by a higher
prevalence of HBV or less effective HBV vaccination programmes in
the country of origin, or limited access to HBV vaccination in
Germany due to language or other barriers or lack of health
insurance (Lutgehetmann et al., 2010).
Ever having been in OST was not significantly associated with
HBV infection status in the MVA and indicates that opportunities to
vaccinate OST recipients against HBV are currently not optimized.
Reasons might be that awareness is low, because medical doctors
offering OST are often not trained in infectious diseases and the
dogma that people receiving OST are supposed to stop theirLeipzig. MD, medical doctor; OST, opioid substitution therapy. *OST service includes
Table 6
Univariable and multivariable analysis of factors associated with not having HBV vaccine-induced antibodies (n = 1561).
No vaccination-induced HBV antibodies detected Univariable analysis Multivariable analysis
OR 95% CI aOR 95% CI
Study city Frankfurt 64% Ref. Ref.
Hanover 23% 0.2 *** 0.1–0.3 0.2 *** 0.1–0.3
Munich 32% 0.3 *** 0.2–0.4 0.3 *** 0.2–0.4
Hamburg 42% 0.4 *** 0.3–0.6 0.4 *** 0.3–0.6
Cologne 66% 1.1 0.7–1.6 1.1 0.8–1.7
Essen 66% 1.1 0.7–1.6 1.1 0.7–1.8
Leipzig 73% 1.5 0.9–2.4 1.8 * 1.1–3.0
Berlin 82% 2.5 *** 1.7–3.8 2.7 *** 1.8–4.1
Sex Male 58% Ref. Ref.
Female 53% 0.8 0.6–1.0 1 0.7–1.2
Age (years) <25 48% Ref. Ref.
25–39 60% 1.6 * 1.1–2.3 1.9 ** 1.2–2.9
40 55% 1.3 0.9–2.0 1.7 * 1.1–2.8
Education Low 55% Ref. Ref.
Middle 58% 1.1 0.9–1.3 1.2 0.9–1.5
High 75% 2.4 ** 1.3–4.7 2.8 ** 1.4–5.6
Other 59% 1.2 0.6–2.3 1.7 0.8–3.5
Ever incarcerated No 51% Ref.
Yes 58% 1.3 * 1.0–1.7
Ever in opioid substitution therapy Yes 55% Ref.
No 63% 1.4 * 1.1–1.8
HBV, hepatitis B virus; OR, odds ratio; aOR, adjusted odds ratio; CI, confidence interval.
* p < 0.05.
** p < 0.01.
*** p < 0.001.
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might be associated with riskier sexual and unsafe use behaviours
(Tavitian-Exley et al., 2015); however, not using a condom during
the last sexual intercourse did not seem to be associated with HBV
infection status. This might indicate that the last intercourse is not
a good proxy for life-time sexual risk behaviour or that sexual
transmission is not the main route of HBV transmission in this
group.
PWID aged 25 years or with a higher education level were less
likely to have detectable vaccine-induced HBV antibodies. An
association with high education level was not expected, although
scepticism towards vaccination has been observed in persons with
higher levels of education in other studies (Wei et al., 2009).
However, due to the cross-sectional design of this study, drawing
strong conclusions regarding whether different socio-demograph-
ic and behavioural factors are the cause or effect of HBV infection
and vaccination is not possible.
Neither having been incarcerated nor being in OST was
significantly associated with showing vaccine-induced HBV anti-
bodies in the MVA, although these could be appropriate settings to
target PWID for HBV vaccination. Most participants had received
their last HBV vaccination from medical doctors not offering
addiction therapy, and few had been vaccinated at low-threshold
drug services, during rehabilitation/long-term addiction therapy,
or in prison, indicating that these settings should be better utilized
to improve HBV vaccination rates among PWID in Germany. The
completion of a vaccination schedule would be easily feasible, e.g.
during OST, due to the regular contact with medical staff.
The MVA revealed a strong association of the study city
particularly with HBV vaccination, and less with infection status,
indicating an effect of the local setting. In a setting where the
proportion of HBV-infected PWID is low (and the proportion of
vaccinated PWID high), the transmission of HBV is less likely to
occur. Furthermore, local differences in practices of medicaldoctors offering OST, local HBV vaccination, and information
campaigns/programmes, e.g. in low-threshold drug services, may
also play a role here and need to be examined in further studies to
evaluate the differences in the study cities and their impact.
Options to increase vaccination coverage among PWID, as
recommended by the WHO and EMCDDA, include the immediate
availability of on-site vaccination during information and vaccina-
tion campaigns targeting PWID, prison-based vaccination pro-
grammes, cash incentives, and accelerated immunization
schedules (Campbell et al., 2007; Sutton et al., 2006; Weaver
et al., 2014; Shah et al., 2015); however, these are not routinely
implemented in Germany. Integrating vaccination campaigns into
needle exchange programmes may also be a cost-effective option
(Hu et al., 2008).
The self-reported HBV infection and vaccination status had
limited validity, with 71% of participants reporting their HBV status
and only 45% reporting their HBV vaccination status in concor-
dance with the laboratory tests. This discordance between self-
reported and tested results has been reported in previous studies
among PWID (Topp et al., 2009). Similarly, among those with a
chronic HCV infection, 73% reported their correct HCV status
(Nielsen et al., 2016). Discordant results also included participants
falsely assuming an HBV infection, probably due to confusing HBV
with HCV. About 20% of study participants assumed that they were
vaccinated against HBV, but showed neither vaccine- nor infec-
tion-induced antibodies, most probably leaving them at risk of HBV
infection. Explanations for this might be confusing HBV vaccina-
tion with other vaccinations, or insufficient protection due to
incomplete vaccination schedules. Furthermore, primary (non-
response) or secondary (waning of antibodies) vaccination failure
cannot be excluded as possible explanations for the lack of
detection of vaccine-induced HBV antibodies. This would lead to an
underestimation of the vaccination prevalence, but might also
reflect the problem of inadequate immune response to HBV
12 J.M. Haussig et al. / International Journal of Infectious Diseases 66 (2018) 5–13vaccination previously described among PWID (Kamath et al.,
2014).
Although all methodologies were validated, a limitation in the
direct comparability of test results from the pilot cities and the
remaining six cities cannot be excluded due to the change of the
laboratory and the methodologies used for testing (Zimmermann
et al., 2014). The assessment of all serological test systems for HBV
showed good accordance between directly tested serum samples
in comparison to DBS, except for anti-HBs in weakly positive sera.
Weakly anti-HBs-positive samples could have been missed with
this procedure. Thus the prevalence of anti-HBs antibodies, e.g. of
HBV vaccinated individuals, based on the DBS technique must be
considered as a conservative estimate, especially in HIV-positive
persons (Ross et al., 2013). However, the anti-HBc results
demonstrated high accuracy of the test systems and yielded
comparable validation results. Furthermore, natural boosting with
HBV can be expected among PWID, and choosing a low threshold
for the detection of anti-HBs should help minimize the underesti-
mation of HBV vaccination.
Although data were anonymized, participants might have been
reluctant to report sensitive data such as unsafe use and sexual
behaviours correctly, and answers might have been influenced by
social desirability bias. RDS is an adequate sampling method to
reach PWID. However, after evaluating the method in this study, it
was decided against presenting RDS-weighted results, as some of
the necessary assumptions for weighting were not fulfilled in all
study cities (Wenz et al., 2016). Selection bias due to oversampling
of persons with communicative competence and who understood
the study flow cannot be excluded.
This study indicates that despite national vaccination recom-
mendations including both the recommendation of universal
infant and child vaccination (since 1995) and risk group vaccina-
tion (starting in 1982), many PWID are still at risk of HBV in
Germany. Targeted information campaigns on HBV and HBV
prevention for healthcare and community workers and medical
doctors in contact with PWID, as well as for the PWID themselves,
need to be intensified. PWID should be tested and counselled
regularly for HBV, and if tested positive, linked to clinical care to
assess the indication for treatment. Testing should be followed by a
discussion of the results in more detail with the patients, and
differences between HBV and HCV should be elucidated. Knowl-
edge of the exact status is further important to avoid risk-taking
behaviours. As the self-reported HBV vaccination status is not
reliable, pre-emptive HBV vaccination should be considered if no
vaccination record is available. Other options with promising
results in other countries and recommended by the WHO and
EMCDDA include a contingency management approach (Weaver
et al., 2014), a ‘don’t ask, vaccinate’ strategy (Day et al., 2010), and
the importance of on-site availability of the vaccination being
critical for uptake in a low-threshold setting (Campbell et al.,
2007).
In order to avoid primary vaccination failure, the STIKO
recommends control testing of anti-HBs antibody titres at 4–8
weeks after the last vaccination dose, and if titres remain too low
(<100 IU/l), further booster vaccinations should be applied (Robert
Koch-Institut (RKI), 2014).
Many study participants had been incarcerated (city range 73–
86%) or were currently or previously in OST (city range 55–89%)
(Wenz et al., 2016). Ensuring routinely offered HBV vaccination to
PWID in these settings would likely improve HBV vaccination rates
among PWID in Germany. An additional advantage of vaccinating
during OST and incarceration is that in these settings, the
completion and documentation of a vaccination course are more
feasible than in the low-threshold system. Nonetheless, vaccina-
tion campaigns in low-threshold drug services are important toraise awareness and to reach those people not in contact with
medical services, and should also be scaled-up.
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